## **Researcher Information Form**

Name: Xiaoting Zhang

**Department/Division/College:** Cancer Biology/COM

## Room/Address:

The Vontz Center for Molecular Studies Room 2316 University of Cincinnati College of Medicine 3125 Eden Avenue Cincinnati, OH 45267-0521

**Phone: 5**13-558-3017

**Email:** zhangxt@ucmail.uc.edu

## **Research Interest** (1-2 Sentences):

My laboratory focuses on understanding the molecular mechanism of gene expression regulation in breast cancer metastasis and therapeutic resistance, and developing RNA-based nanotherapeutics for the treatment of human breast cancer.

**Unique Resources/Techniques:** MED1 overexpression, knockin and conditional knockout mice/RNA Nanotechnology

## **Representative Publications** (5 Maximum, May use Hyperlink):

Jiang P, Hu Q, Ito M, Meyer S, Waltz S, Khan S, Roeder RG and **Zhang X**. Key Role of MED1/TRAP220 LxxLL Motifs in Pubertal Mammary Gland Development and Luminal-Cell Differentiation. *Proc. Natl. Acad. Sci. U S A* (2010) 107:6765-6770.

Cui J, Germer K, Wu T, Wang J, Luo J, Wang SC, Wang Q, and **Zhang X**. Crosstalk Between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells. *Cancer Research* (2012) 72:5625-5634.

Zhang Y, Leonard M, Shu Y, Yang Y, Shu D, Guo P, and **Zhang X.** Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles. (2017) ACS Nano 11(1):335-346.

Yang Y, Leonard M, Zhang Y, Zhao, D, Mahmoud C, Khan S, Wang J, Lower EE, and **Zhang X**. HER2-driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator (2018) Cancer Research 78(2):422-435.

**Zhang, X.** Editor (2019) Estrogen Receptor and Breast Cancer–Celebrating the 60th Anniversary of the Discovery of ER (Cancer Drug Discovery and Development) 1st ed. Springer Nature